Chihiro Shiraishi 研究室

主宰者：Chihiro Shiraishi

福岡大学

AI 要約（直近 5 年の研究成果）

白石研究室では、医薬品の安全性を大規模なデータベースを用いて調査する研究に取り組んでいます。特に、米国医食品医薬品局の医薬品有害事象報告システムなどの膨大な臨床記録から、複数の医薬品の副作用パターンを比較分析しています。抗生物質、抗てんかん薬、免疫抑制薬、抗がん薬など様々な治療薬を対象に、薬剤間の安全性プロファイルの違いを明らかにする統計的手法を活用しています。同時に、患者の個別の臨床データを用いた後ろ向き観察研究も展開しており、特定の治療状況における医薬品の有効性と安全性を詳細に検討しています。腎移植や膵臓・腎臓同時移植などの臓器移植患者における免疫抑制療法、肺炎や敗血症患者の抗菌薬治療、化学療法に伴う悪心・嘔吐の制御など、臨床上の重要な課題を対象としています。さらに、薬物相互作用の仕組みを薬物動態モデルや遺伝子データベースを組み合わせて解析し、医薬品の体内での処理過程から有害事象の発生メカニズムを探究しています。これらの多角的なアプローチにより、患者の安全性向上と医療の質的改善に貢献する基礎的知見を得ることを目指しています。

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

外部リンク

研究成果（45 件）

[2026] Clinical Course and Risk Factors of Lenvatinib‐Related Hypothyroidism in Hepatocellular Carcinoma: A Retrospective Cohort Study
DOI: https://doi.org/10.1002/cnr2.70461
[2026] Relationship Between Trimethoprim‐Sulfamethoxazole‐Induced Hepatotoxicity and Cytochrome Protein 450 2C9 Using Food and Drug Administration Adverse Event Reporting System Database
DOI: https://doi.org/10.1155/jcpt/8891620
[2026] Safety of Short-Term Low-Dose Olanzapine in Patients with Cancer and Diabetes Receiving Cisplatin-Based Chemotherapy: A Retrospective TriNetX Cohort Study
DOI: https://doi.org/10.2147/dddt.s615968
[2026] Clinical outcomes of daptomycin in patients with augmented renal clearance: a case series
DOI: https://doi.org/10.1016/j.jiac.2026.103005
[2026] Comparative Adverse Event Reporting of Asparaginase-Containing Induction Regimens in Pediatric Acute Lymphoblastic Leukemia Using the United States Food and Drug Administration Adverse Event Reporting System
DOI: https://doi.org/10.7759/cureus.108119
[2026] Hypothesis-Generating Analysis of Four Immunosuppressive Regimens After Simultaneous Pancreas-Kidney Transplantation Using the United States Food and Drug Administration Adverse Event Reporting System
DOI: https://doi.org/10.7759/cureus.107193
[2026] Reporting patterns of renal failure associated with immunosuppressant combinations following liver transplantation: a retrospective analysis
DOI: https://doi.org/10.4285/ctr.25.0051
[2026] Cholecalciferol Supplementation and Transplant Outcomes Across Immunosuppressive Regimens in Renal Transplant Recipients Using the United States Food and Drug Administration Adverse Event Reporting System
DOI: https://doi.org/10.7759/cureus.105141
[2026] Comparative Safety of Six First-Line Antiepileptic Monotherapies in Pediatric Epilepsy Using the United States FDA Adverse Event Reporting System
DOI: https://doi.org/10.7759/cureus.105027
[2026] Comparison of Adverse Events Associated With Six Common Antibiotics in Lower Respiratory Tract Infections Using the United States Food and Drug Administration Adverse Event Reporting System
DOI: https://doi.org/10.7759/cureus.103809

続きを表示（残り 35 件）

[2026] Comparative effectiveness of two first-line, ICI-based regimens for advanced HCC: a target trial emulation using an electronic medical record network
DOI: https://doi.org/10.3389/fonc.2026.1776032
[2026] Multiple-day dexamethasone for controlling delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy
DOI: https://doi.org/10.1186/s12885-026-15555-9
[2026] Impact of everolimus-based immunosuppression on transplant rejection or death in lung transplant recipients using the United States Food and Drug Administration Adverse Event Reporting System
DOI: https://doi.org/10.1016/j.trim.2026.102345
[2025] Impact of Acid Suppressants on the Development of Clostridioides difficile Infection and Possible Preventive Effects of Probiotic Formulations
DOI: https://doi.org/10.2147/idr.s543864
[2025] Mannitol versus furosemide for prevention of cisplatin-induced nephrotoxicity in a multicenter retrospective cohort study
DOI: https://doi.org/10.1038/s41598-025-25510-6
[2025] Adverse events associated with single-ingredient folic acid in pregnancy: A descriptive analysis of the United States Food and Drug Administration Adverse Event Reporting System (2004–2025)
DOI: https://doi.org/10.1177/02601060251397348
[2025] Influence of renal function and daptomycin dose on clinical effectiveness and adverse events in Japanese pediatric patients: A multicenter retrospective observational study
DOI: https://doi.org/10.1371/journal.pone.0327993
[2025] Effect of Clostridium butyricum and antibiotics using simultaneous simple suspension in mice with Clostridioides difficile infection
DOI: https://doi.org/10.1016/j.yexmp.2025.104979
[2025] Comparing drug combinations for graft-versus-host disease prophylaxis using the U.S. Food and Drug Administration Adverse Event Reporting System
DOI: https://doi.org/10.4285/ctr.24.0049
[2025] Comparison of Adverse Events Among Angiotensin Receptor Blockers in Hypertension Using the United States Food and Drug Administration Adverse Event Reporting System
DOI: https://doi.org/10.7759/cureus.81912
[2025] Comparative Analysis of Adverse Event Profiles Among Seven Statins for Hypercholesterolemia Management Using the United States FDA Adverse Event Reporting System
DOI: https://doi.org/10.7759/cureus.81260
[2025] Prediction of hyperkalemia occurrence in patients using co-trimoxazole: Clinical adjustment of a Markov model
DOI: https://doi.org/10.5414/cp204681
[2025] Changes in the blood cyclosporine level after switching from voriconazole to isavuconazole in a patient with aplastic anemia: insights from physiologically based pharmacokinetic model simulation and the Adverse Event Reporting System database study
DOI: https://doi.org/10.3389/fmicb.2025.1525991
[2025] Approach to Detecting Beneficial and Detrimental Drug-Drug Interactions in Complex Pharmacotherapy
DOI: https://doi.org/10.7759/cureus.78746
[2024] Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database
DOI: https://doi.org/10.1038/s41598-024-63504-y
[2024] An investigation of broad-spectrum antibiotic-induced liver injury based on the FDA Adverse Event Reporting System and retrospective observational study
DOI: https://doi.org/10.1038/s41598-024-69279-6
[2024] Comparison of Adverse Events Following Immunosuppressant Administration for Pediatric Patients With Renal Transplants Categorized by Two-Year Age Increments Using the U.S. Food and Drug Administration Adverse Event Reporting System
DOI: https://doi.org/10.7759/cureus.65300
[2024] Estimation of three-parameter Fréchet distribution for the number of days from drug administration to remission in small sample sizes
DOI: https://doi.org/10.3233/mas-231466
[2024] Efficacy of Prednisone Avoidance in Patients With Liver Transplant Using the U.S. Food and Drug Administration Adverse Event Reporting System
DOI: https://doi.org/10.7759/cureus.60193
[2024] Evaluation of Pharmacy Students’ Understanding of Clinical Trials and Research through Questionnaires Before and After the Hospital Practical Training
DOI: https://doi.org/10.1248/yakushi.23-00202
[2024] Analysis of Adverse Events Following Phenobarbital Administration for Pediatric Patients Categorized by One-Year Age Increments Using the U.S. Food and Drug Administration Adverse Event Reporting System
DOI: https://doi.org/10.7759/cureus.56418
[2024] Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting System
DOI: https://doi.org/10.1080/14740338.2024.2418333
[2024] Association between age and onset of daptomycin-induced adverse events using the U.S. food and drug administration adverse event reporting system
DOI: https://doi.org/10.1016/j.jiac.2024.08.016
[2023] Variations in prothrombin time-international normalized ratio caused by drug-drug interaction in patients receiving warfarin: A retrospective observational study
DOI: https://doi.org/10.5414/cp204306
[2023] Analysis of death avoidance by concomitant use of prednisone in patients with renal transplant using the Food and Drug Administration Adverse Event Reporting System
DOI: https://doi.org/10.1016/j.trim.2023.101900
[2023] Impact of Extracorporeal Membrane Oxygenation in an Infant Treated with Vancomycin: A Case Report
DOI: https://doi.org/10.3390/ijerph20031839
[2023] Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System
DOI: https://doi.org/10.1007/s40261-022-01242-7
[2023] Factors for the development of anemia in patients with newly introduced olaparib: A retrospective case-control study
DOI: https://doi.org/10.1097/md.0000000000034123
[2023] Analysis of Clinical Factors in Olaparib-related Anemia Using Adverse Drug Event Reporting Databases
DOI: https://doi.org/10.21873/anticanres.16231
[2022] Cutoff Value for Wilcoxon-Mann-Whitney Test by Minimum P-value: Application to COVID-19 Data
DOI: https://doi.org/10.5539/ijsp.v11n3p1
[2022] Trichotomization with two cutoff values using Kruskal-Wallis test by minimum P-value approach
DOI: https://doi.org/10.2478/jamsi-2022-0010
[2022] Population kinetic–pharmacodynamic analysis of serum potassium in patients receiving sulfamethoxazole/trimethoprim
DOI: https://doi.org/10.1111/bcpt.13783
[2022] Parameter estimation of Weibull distribution for the number of days between drug administration and early onset adverse event
DOI: https://doi.org/10.1080/10543406.2022.2154940
[2021] Drug-Drug Interaction between Azathioprine and Allopurinol in Patients with Chronic Kidney Disease: A Case Series Study
DOI: https://doi.org/10.1248/bpbreports.4.5_170
[2021] Factors affecting serum phenobarbital concentration changes in pediatric patients receiving elixir and powder formulations
DOI: https://doi.org/10.1186/s40780-021-00190-2

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。

AI 要約（直近 5 年の研究成果）

外部リンク

関連研究室(8 件)

研究成果（45 件）

科研費（0 件）

所属学会・役職（0 件）